Lupin launches generic version of Vimovo in US

Pharma major Lupin Limited announced the launch of an authorised generic version of Horizon Therapeutics PLC's Vimovo delayed action release tablets, 375 mg/20 mg and 500 mg/ 20 mg in the US.

The drug is a combination of Naproxen, a Non-Steroidal Anti-Inflammatory Drug (NSAID) and esomeprazole magnesium, a Proton Pump Inhibitor (PPI) indicated in patients of 12 years of age and older, weighing at least 38 kg, who require Naproxen for symptomatic relief of Arthritis and esomeprazole magnesium to decrease the risk of developing Naproxen-associated gastric ulcers.

According to Quintiles and IMS Health (IQVIA) MAT January 2020, Naproxen and Esomeprazole Magnesium Delayed-Release Tablets or Vimovo, had an annual sale of around US$ 400 million in the US.

Lupin is an innovation-led transnational pharmaceutical company, headquartered in Mumbai (India). The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in various markets.

At 9.20 am on Friday, the stock was trading at Rs 662.20, down by 2.10 per cent or Rs 14.20 per share. The 52-week high is recorded at Rs 882.15 and the 52-week low is Rs 621 on BSE.